58, 59, 60, 61, 62, 63 The wide range of reported concordance rates between IHC and FISH assessment of HER2 status in breast cancer reflects, at least in part, the wide variation in methodology, instrumentation, and experience of the laboratories performing the testing. The sensitivity and ...
Gown AM. Current issues in ER and HER-2 testing by IHC in breast cancer. Mod Pathol. 2008; 21 :S8.Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008; 13 (Suppl 2):S8–S15.Gown AM. Current issues in ER and HER2 testing by IHC in breast ...
receptor status and ERBB2 status of breast carcinoma: a Trastuzumab after adjuvant chemotherapy in HER2- gene-expression profiling study. Lancet Oncol 2007;8: positive breast cancer. N Engl J Med 2005;353: 203–211. 1659–1672. 24 Schnitt SJ. Estrogen receptor testing of breast cancer in 40...
[3]Wolff A C,Hammond M E,Schwartz J N,et al.American Society of Clinical Oneology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].Arch Pathol Lab Med,2007,131(1):18-43. [4]Geyer F C,Marchio C,Reis-Filho...
(breast cancer)或乳癌(breast carcinoma [0035] )、头颈癌、结直肠癌、膀胱癌、肺癌、胃肠道间质瘤(gastrointestinal stromal tumor,GIST)、前列腺癌、宫颈癌或肾细胞癌,或者所述肿瘤或癌症是侵袭性或转移性乳癌 或乳腺癌;和/或 [0036] ‑所述组织样品是活检样品,或者所述组织样品是或来源于穿刺活检样品,或者...
[26] Hunter, Katerina Ancevski, Mark A. Socinski, and Liza C. Villaruz. PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer. Molecular diagnosis & therapy 22.1 (2018): 1-10. [27] Hirs...
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC sco... . High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized ...
Pathology Research, director, Tissue Microarray Facility, director, Yale Pathology Tissue Services, Pathology, Yale Cancer Center, discusses the limitations of current HER2 immunohistochemistry (IHC) assays in breast cancer, and how inaccurate testing results impact outcom...
Rigorous testing on a publicly available breast cancer dataset demonstrates superior performance compared to existing methods, establishing our model as a state-of-the-art solution in advancing pathology image translation from H&E to IHC staining. 展开 ...
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer HER2+ rates were 10.1% (15/148) by IHC, 18.2% (27/148) by FISH+ or 21.6% (32/148) by dc-SISH+. There were significant differences in HER2+... C Gomez-Martin,E Garralda,M...